CC Investor Notification: Chemours Sued for Securities Fraud on behalf of Investors with Losses after Opteon Demand Issues Lead to 18% Stock Drop
Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class...
Covered in this story
Analyst targets on Chemours
- RBC Capital Markets: at $13.4 · target $14 by Oct 2027 · Sector Perform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Chemours →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.